EGFR and bone metastasis: In subgroup analyses, the EGFR mutation (−) group confirmed the significance of BMA for better post-bone metastasis survival: BMA (−) n = 28, median post-bone metastasis survival 7.2 months (95% CI: 3.4–12.9); BMA (+) n = 39, median post-bone metastasis survival 13.6 months (95% CI: 6.0–27.1) (p < 0.05) (Figure 3D).